Business Context and Reporting Period
This Form 8-K was filed by AVROBIO, Inc. (noting a discrepancy in the request metadata which listed "Tectonic Therapeutic, Inc.") on October 4, 2022. The report addresses a regulatory notice regarding the continued listing of the Company's common stock on The Nasdaq Global Select Market.
Key Financial Metrics
This filing is a current report regarding listing compliance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material event reported is the receipt of a written notice from Nasdaq staff indicating non-compliance with the Minimum Bid Price Requirement (Rule 5450(a)(1)). Specifically:
- The Company's common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days between August 22, 2022, and October 3, 2022.
- An indicator of non-compliance has been displayed with the Company's quotation information on Nasdaq platforms.
Outlook, Risks, and Management Commentary
Compliance Period: The Company has been granted an initial 180-day compliance period, ending on April 3, 2023, to regain compliance. To do so, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days.
Future Options and Risks:
- If compliance is not achieved by the deadline, the Company may be eligible for an additional 180-day period, contingent upon transferring its listing to The Nasdaq Capital Market and meeting specific market value standards.
- The Company may consider a reverse stock split to cure the deficiency.
- There is no assurance that the Company will regain compliance or that an appeal of a potential delisting determination would be successful.
Management Action: The Company intends to monitor the closing bid price and consider available options to regain compliance.
Investor Verification Checklist
- Verify the current trading price of AVRO common stock to assess proximity to the $1.00 threshold.
- Monitor future filings for announcements regarding a potential reverse stock split or transfer to The Nasdaq Capital Market.
- Review the Company's most recent 10-K or 10-Q for actual financial health metrics (cash runway, burn rate) as this 8-K contains none.
- Check for any subsequent Nasdaq notices regarding the status of the compliance period or delisting proceedings.